Monday, August 24, 2026

NRIX 2026-08-24

Nurix Therapeutics: Roche Has Changed The Economics Of The Bull Case

NRIX $2.9B

Equity Eagle 25h ago

Stripe’s “Singularity” and the Divergence from Adyen

ADYEY $39B

MBI Deep Dives 26h ago

The Junk (Mail) Merger Arb

STRR $37M

Triple S Special Situations Investing 29h ago

From X

@catechwilliams May 23

catechwilliams on X

Meanwhile disintermediation by OEMs going direct is accelerating. See recent commentary from partners $CSCO, $PANW $DELL, etc. $PLUS has zero discernable benefit from $NVDA and AI.

@catechwilliams May 23

catechwilliams on X

Answer: aggressive revenue booking, financing sales, selling products at/ below cost to boost revenue and hoping to “then try to build it back up over time” per CEO. Contrast $PLUS performance w competitor and industry leader $CDW.

@catechwilliams May 23

catechwilliams on X

$PLUS Numbers don’t add up. 50% sales $CSCO product (sales -13% MRQ, guided -11%). MRQ $PLUS sales +13% (reported yesterday). Earnings call question: “OEM Cisco have talked about bottlenecks, weak orders. You’ve been unscathed…how are you outperforming the market significantly?”

@catechwilliams May 22

catechwilliams on X

$EXLS Highly innovative founder-CEO rapidly taking share w AI-based services. High-teens topline growth w expanding margins, higher value-add mix to attractive end-markets. 17x P/E yet to reflect business transformation. 100% FCF to buybacks. Winning customers from $ACN $DXC $WIT

@catechwilliams May 3

catechwilliams on X

$OII Niche leader in subsea robotics at 12x P/E. Offshore rig count accelerating (70% share), A&D growing DD, new autonomous tech a major growth driver in other end markets (lifts, etc). Investor day next week will showcase products and new LT targets. >50% NTM upside, IMO.

@catechwilliams Apr 30

catechwilliams on X

SRS is a private-equity rollup of landscaping, pool and roofing distributors, lacking exclusive supplier relationships and serving smaller homebuilders.

@catechwilliams Apr 30

catechwilliams on X

$GMS Underfollowed building products distributor, HSD growth, favorable mix shift/ margin, tracking to beat estimates, trading at 10x EPS, 7x EBITDA. Peers at >50% higher multiples. $HD just acquired lower quality peer SRS for 17x EBITDA. GMS = $240 or +150% at that multiple.

@catechwilliams Apr 24

catechwilliams on X

$CVGW Situation getting : 1) being investigated by SEC, DOJ for bribery, cartel dealings, 2) intensely competitive biz, losing customers/ share w zero earnings; 3) sale of struggling prepared segment faltering. None of this is priced-in yet. Next 2 quarters likely a disaster.